Cerebrospinal Fluid Protein Biomarkers for Alzheimer's Disease

被引：296

作者：

Blennow K. ^{[1
]}

机构：

[1] Department of Clinical Neuroscience, Section of Experimental Neuroscience, The Sahlgrenska Academy

来源：

NeuroRX | 2004年 / 1卷 / 2期

关键词：

β-amyloid; Alzheimer's disease; biomarker; cerebrospinal fluid; phosphorylated tau; tau;

D O I：

10.1602/neurorx.1.2.213

中图分类号：

学科分类号：

摘要：

The introduction of acetylcholine esterase (AChE) inhibitors as a symptomatic treatment of Alzheimer's disease (AD) has made patients seek medical advice at an earlier stage of the disease. This has highlighted the importance of diagnostic markers for early AD. However, there is no clinical method to determine which of the patients with mild cognitive impairment (MCI) will progress to AD with dementia, and which have a benign form of MCI without progression. In this paper, the performance of cerebrospinal fluid (CSF) protein biomarkers for AD is reviewed. The diagnostic performance of the three biomarkers, total tau, phospho-tau, and the 42 amino acid form of β-amyloid have been evaluated in numerous studies and their ability to identify incipient AD in MCI cases has also been studied. Some candidate AD biomarkers including ubiquitin, neurofilament proteins, growth-associated protein 43 (neuromodulin), and neuronal thread protein (AD7c) show interesting results but have been less extensively studied. It is concluded that CSF biomarkers may have clinical utility in the differentiation between AD and several important differential diagnoses, including normal aging, depression, alcohol dementia, and Parkinson's disease, and also in the identification of Creutzfeldt-Jakob disease in cases with rapidly progressive dementia. Early diagnosis of AD is not only of importance to be able to initiate symptomatic treatment with AChE inhibitors, but will be the basis for initiation of treatment with drugs aimed at slowing down or arresting the degenerative process, such as γ-secretase inhibitors, if these prove to affect AD pathology and to have a clinical effect. © 2004 The American Society for Experimental NeuroTherapeutics, Inc.

引用

页码：213 / 225

页数：12

共 148 条

[1] Blennow K., Skoog I., Genetic testing for Alzheimer's disease: how close is reality?, Curr Opin Psychiatry, 12, pp. 487-493, (1999)
[2] Tomlinson B., Blessed G., Roth M., Observations on the brains of demented old people, J Neurol Sci, 11, pp. 205-242, (1970)
[3] Davies L., Wolska B., Hilbich C., Multhaup G., Martins R., Simms G., Et al., A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques, Neurology, 38, pp. 1688-1693, (1988)
[4] McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E., Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of department of health and human services task force on Alzheimer's disease, Neurology, 34, pp. 939-944, (1984)
[5] Petersen R., Smith G., Waring S., Ivnik R., Tangalos E., Kokmen E., Mild cognitive impairment: clinical characterization and outcome, Arch Neurol, 56, pp. 303-308, (1999)
[6] DeCarli C., Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment, Lancet Neurol, 2, pp. 15-21, (2003)
[7] Blennow K., Wallin A., Clinical heterogeneity of probable Alzheimer's disease, J Geriatr Psychiatry Neurol, 5, pp. 106-113, (1992)
[8] Goedert M., Spillantini M., Potier M., Ulrich J., Crowther R., Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain, EMBO J, 8, pp. 393-399, (1989)
[9] Buee L., Bussiere T., Buee-Scherrer V., Delacourte A., Hof P., Tau protein isoforms, phosphorylation and role in neurodegenerative disorders, Brain Res Brain Res Rev, 33, pp. 95-130, (2000)
[10] Iqbal K., Alonso Adel C., El-Akkad E., Gong C., Haque N., Et al., Pharmacological targets to inhibit Alzheimer neurofibrillary degeneration, J Neural Transm Suppl, 62, pp. 309-319, (2002)

← 1 2 3 4 5 6 7 8 9 10 →